Format

Send to

Choose Destination
Gastroenterology Res. 2013 Aug;6(4):124-133. Epub 2013 Sep 9.

Oral Administration of Interleukin-10 and Anti-IL-1 Antibody Ameliorates Experimental Intestinal Inflammation.

Author information

1
Department of Medical Biotechnology and Translation Medicine, Universita degli Studi di Milano,Via Vanvitelli 32, 20133 Milan, Italy.
2
Scott and White Healthcare Temple Texas, Via Celoria 10, 20133 Milan, Italy.
3
Dipartimento di Scienze Veterinarie per la Salute, la Produzione Animale e la Sicurezza Alimentare, Via Celoria 10, 20133 Milan, Italy.
4
Dipartimento di Informatica e Comunicazione, Universita degli Studi di Milano, Milan, Italy.
5
Dipartimento di Scienze Biomediche per la Salute, Universita degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy; WHO Coll. Center for Traditional Medicine, CREBION, Centro Interdipartimentale di Ricerca per lo studio degli Effetti Biologici delle Nano-concentrazioni. Via Celoria 10, 20133 Milan, Italy.
6
Department of Medical Biotechnology and Translation Medicine, Universita degli Studi di Milano,Via Vanvitelli 32, 20133 Milan, Italy; WHO Coll. Center for Traditional Medicine, CREBION, Centro Interdipartimentale di Ricerca per lo studio degli Effetti Biologici delle Nano-concentrazioni. Via Celoria 10, 20133 Milan, Italy.

Abstract

BACKGROUND:

To elucidate the effects of a solution containing interleukin-10 and anti-IL-1 antibody in modulating experimental intestinal inflammation.

METHODS:

Colitis was induced in BALB/c mice by oral administration of dextran sodium sulphate; mice were then treated with interleukin-10 plus anti-IL-1 antibody at low dosage. Transepithelial electrical resistance of isolated mouse colon and colon lengths were evaluated. Cytokines concentrations in organocultures supernatants and plasma samples were evaluated by Enzyme-Linked Immuno Sorbent Assay. Tight junction proteins were evaluated by immunofluorescence, respectively.

RESULTS:

Oral administration of tested products restores intestinal barrier function during experimental intestinal inflammation in association with reduced levels of proinflammatory cytokines, increased interleukin-10 plasma concentrations and a tight junction architecture restoration.

CONCLUSION:

Obtained results may contribute to modelling an interesting strategy for the treatment of patients with inflammatory bowel diseases.

KEYWORDS:

Anti-interleukin-1 alpha antibody; Interleukin-10; Intestinal bowel disease; Low doses; Tight-junctions

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center